Yun-Fan Sun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2293874/publications.pdf

Version: 2024-02-01

304368 243296 3,264 51 22 44 citations h-index g-index papers 52 52 52 4441 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma. Frontiers in Immunology, 2022, 13, 847263.	2.2	1
2	Circulating tumor cell detection and single ell analysis using an integrated workflow based on ChimeraX [®] â€i120 Platform: A prospective study. Molecular Oncology, 2021, 15, 2345-2362.	2.1	9
3	Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver International, 2021, 41, 562-573.	1.9	32
4	Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell, 2021, 184, 404-421.e16.	13.5	399
5	Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NFâ€kB signaling pathways synergistically. Clinical and Translational Medicine, 2021, 11, e335.	1.7	27
6	An Oxygen-Concentration-Controllable Multiorgan Microfluidic Platform for Studying Hypoxia-Induced Lung Cancer-Liver Metastasis and Screening Drugs. ACS Sensors, 2021, 6, 823-832.	4.0	28
7	scDPN for High-throughput Single-cell CNV Detection to Uncover Clonal Evolution During HCC Recurrence. Genomics, Proteomics and Bioinformatics, 2021, 19, 346-357.	3.0	3
8	Abstract 486: A phase lb/II, open-label study evaluating the efficacy and safety of Toripalimab injection (JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC). Cancer Research, 2021, 81, 486-486.	0.4	7
9	Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. Nature Communications, 2021, 12, 4091.	5.8	90
10	BRCA1-associated protein 1 serves as a tumor suppressor in hepatocellular carcinoma by deubiquitinating and stabilizing PTEN. American Journal of Cancer Research, 2021, 11, 2044-2061.	1.4	0
11	Freehand Minimally Invasive Pedicle Screw Fixation and Minimally Invasive Decompression for a Thoracic or Lumbar Vertebral Metastatic Tumor From Hepatocellular Carcinoma. Frontiers in Surgery, 2021, 8, 723943.	0.6	4
12	Single-cell RNA sequencing reveals spatial heterogeneity and immune evasion of circulating tumor cells. Cancer Biology and Medicine, 2021, 18, 934-936.	1.4	4
13	Establishment of a hepatocellular carcinoma patientâ€derived xenograft platform and its application in biomarker identification. International Journal of Cancer, 2020, 146, 1606-1617.	2.3	32
14	Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. Clinica Chimica Acta, 2020, 511 , $67-74$.	0.5	8
15	Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. EBioMedicine, 2020, 62, 103107.	2.7	23
16	Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A singleâ€center, retrospective, propensityâ€matched study. Clinical and Translational Medicine, 2020, 10, e137.	1.7	25
17	Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death and Disease, 2020, 11, 573.	2.7	65
18	BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity. Cell Death and Disease, 2020, 11, 895.	2.7	11

#	Article	IF	CITATIONS
19	USP1 Maintains the Survival of Liver Circulating Tumor Cells by Deubiquitinating and Stabilizing TBLR1. Frontiers in Oncology, 2020, 10, 554809.	1.3	11
20	Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. Cancer Cytopathology, 2020, 128, 733-745.	1.4	19
21	Abstract 5380: An integrated platform for the clinical detection and molecular profiling of single circulating tumor cells. , 2020, , .		1
22	KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. Journal of Cancer, 2019, 10, 3914-3925.	1.2	27
23	Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target. BMC Cancer, 2019, 19, 760.	1.1	78
24	Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity scoreâ€matched survival analysis. Cancer Medicine, 2019, 8, 6933-6944.	1.3	14
25	Phosphorylase Kinase \hat{l}^2 Represents a Novel Prognostic Biomarker and Inhibits Malignant Phenotypes of Liver Cancer Cell. International Journal of Biological Sciences, 2019, 15, 2596-2606.	2.6	15
26	CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of $P110\hat{l}^2$ and predicts poor prognosis. Journal of Hematology and Oncology, 2019, 12, 37.	6.9	150
27	Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2019, 8, 582-596.	0.7	17
28	Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. Oncologist, 2019, 24, 997-1007.	1.9	9
29	The heterogeneity of genomic biomarkers for immune checkpoint inhibitor in therapy-naÃ ⁻ ve primary hepatocellular carcinoma and their metachronous metastases Journal of Clinical Oncology, 2019, 37, e15665-e15665.	0.8	0
30	Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology, 2018, 25, 1686-1694.	0.7	25
31	Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma. Clinical Cancer Research, 2018, 24, 2203-2213.	3.2	102
32	Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma. Clinical Cancer Research, 2018, 24, 547-559.	3.2	112
33	BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. Cell Death and Disease, 2018, 9, 1036.	2.7	31
34	PDXliver: a database of liver cancer patient derived xenograft mouse models. BMC Cancer, 2018, 18, 550.	1.1	20
35	Circulating CD14 ⁺ HLAâ€DR ^{â^'/low} myeloidâ€derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. Hepatology Research, 2017, 47, 1061-1071.	1.8	56
36	HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma. Oncotarget, 2017, 8, 47121-47135.	0.8	29

#	Article	IF	CITATIONS
37	Low expression is associated with poor prognosis in patients with hepatocellular carcinoma. American Journal of Cancer Research, 2017, 7, 2465-2477.	1.4	5
38	Prognostic value of fever grade combined with neutrophil percentage in hepatocellular carcinoma patients presenting fever as the initial manifestation. OncoTargets and Therapy, 2016, Volume 9, 6281-6290.	1.0	5
39	Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. Oncotarget, 2016, 7, 70654-70668.	0.8	44
40	Distinguished prognosis after hepatectomy of HBV-related hepatocellular carcinoma with or without cirrhosis: a long-term follow-up analysis. Journal of Gastroenterology, 2016, 51, 722-732.	2.3	19
41	Downregulation and pro-apoptotic effect of hypoxia-inducible factor 2 alpha in hepatocellular carcinoma. Oncotarget, 2016, 7, 34571-34581.	0.8	25
42	Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma. Cancer Letters, 2015, 366, 112-122.	3.2	21
43	A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2015, 468, 525-532.	1.0	59
44	Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 2014, 20, 6212-6222.	3.2	1,012
45	Clinical Significance of <i>EpCAM</i> mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR–Based Platform. Clinical Cancer Research, 2014, 20, 4794-4805.	3.2	99
46	The biological characteristics and kinetics of circulating tumor cells in hepatocellular carcinoma undergoing surgical interventions Journal of Clinical Oncology, 2014, 32, e22013-e22013.	0.8	0
47	The heterogeneity and clinical relevance of circulating tumor-initiating cells in hepatocellular carcinoma using an integrated immunomagnetic-microfluidic platform Journal of Clinical Oncology, 2014, 32, e15132-e15132.	0.8	0
48	Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology, 2013, 57, 1458-1468.	3.6	331
49	Impact of deviated balance of regulatory and cytotoxic T cells on release and reseeding of circulating tumor cells in hepatocellular carcinoma Journal of Clinical Oncology, 2013, 31, e22133-e22133.	0.8	0
50	Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1151-1173.	1.2	160
51	Elaborating the Tumor Ecosystem of Primary and Relapsed Hepatocellular Carcinoma by Single-Cell RNA Sequencing. SSRN Electronic Journal, 0, , .	0.4	0